BrightPath Biopharma

BrightPath Biopharma is a clinical-stage biotechnology company based in Japan, specializing in the development of next-generation cancer immunotherapies. The company's diverse portfolio includes cancer peptide vaccines, cell therapies such as CAR-T and iPSC-derived NKT cells, and therapeutic antibodies. Their lead programs focus on treating solid tumors, including non-small cell lung cancer and head and neck cancers, by leveraging the body's immune system to target specific cancer antigens. BrightPath is publicly traded on the Tokyo Stock Exchange and maintains strong collaborations with academic institutions to advance its innovative pipeline. The company aims to provide curative treatments for cancer patients who do not respond to existing therapies.